ME02892B - Hemijska jedinjenja - Google Patents
Hemijska jedinjenjaInfo
- Publication number
- ME02892B ME02892B MEP-2017-292A MEP2017292A ME02892B ME 02892 B ME02892 B ME 02892B ME P2017292 A MEP2017292 A ME P2017292A ME 02892 B ME02892 B ME 02892B
- Authority
- ME
- Montenegro
- Prior art keywords
- fluoro
- pyrido
- indol
- phenyl
- methylpropyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 16
- 150000003839 salts Chemical class 0.000 claims 12
- DFBDRVGWBHBJNR-BBNFHIFMSA-N (e)-3-[3,5-difluoro-4-[(1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H](N2CC(C)(C)F)C)=C(F)C=C(\C=C\C(O)=O)C=C1F DFBDRVGWBHBJNR-BBNFHIFMSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- QZKOBFIEGIQDMU-MYSGNRETSA-N (E)-3-[3,5-difluoro-4-[(3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-3,4-dihydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical compound C([C@H]([N+]=1CC(C)(C)F)C)c(c2c(cccc2)[nH]2)c2C=1c1c(F)cc(\C=C\C([O-])=O)cc1F QZKOBFIEGIQDMU-MYSGNRETSA-N 0.000 claims 1
- STVQFMFTCUMADM-XGMWYDOHSA-N (e)-3-[3,5-difluoro-4-[(1r,3r)-2-[(2s)-3-fluoro-2-methylpropyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H](C)N2C[C@@H](CF)C)=C(F)C=C(\C=C\C(O)=O)C=C1F STVQFMFTCUMADM-XGMWYDOHSA-N 0.000 claims 1
- AKZLESYLLLKGNZ-MDZDMXLPSA-N (e)-3-[3,5-difluoro-4-[2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1=2NC3=CC=CC=C3C=2CC(C)(C)N(CC(C)(F)C)C1C1=C(F)C=C(\C=C\C(O)=O)C=C1F AKZLESYLLLKGNZ-MDZDMXLPSA-N 0.000 claims 1
- XTDHJGCTXMSPCY-RSEBSXLISA-N (e)-3-[3,5-difluoro-4-[2-[(2s)-3-fluoro-2-methylpropyl]-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1=2NC3=CC=CC=C3C=2CC(C)(C)N(C[C@@H](CF)C)C1C1=C(F)C=C(\C=C\C(O)=O)C=C1F XTDHJGCTXMSPCY-RSEBSXLISA-N 0.000 claims 1
- IOPRLAHXDGSIHG-NAUGMMEESA-N (e)-3-[3-fluoro-4-[2-[(2s)-3-fluoro-2-methylpropyl]-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1=2NC3=CC=CC=C3C=2CC(C)(C)N(C[C@@H](CF)C)C1C1=CC=C(\C=C\C(O)=O)C=C1F IOPRLAHXDGSIHG-NAUGMMEESA-N 0.000 claims 1
- DFBDRVGWBHBJNR-NYKMLEKOSA-N (e)-3-[4-[(1r,3r)-1-deuterio-2-(2-fluoro-2-methylpropyl)-3-methyl-4,9-dihydro-3h-pyrido[3,4-b]indol-1-yl]-3,5-difluorophenyl]prop-2-enoic acid Chemical class C1([C@@]2(C3=C(C4=CC=CC=C4N3)C[C@@H](C)N2CC(C)(C)F)[2H])=C(F)C=C(\C=C\C(O)=O)C=C1F DFBDRVGWBHBJNR-NYKMLEKOSA-N 0.000 claims 1
- HYPDMBONKGTBLC-NVEBTIFVSA-N (e)-3-[4-[(1r,3r)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H](N2CC(C)(C)F)C)=CC=C(\C=C\C(O)=O)C=C1 HYPDMBONKGTBLC-NVEBTIFVSA-N 0.000 claims 1
- CLDCRFJRMORRTI-IEGMAYJBSA-N (e)-3-[4-[(1r,3r)-2-[(2s)-3-fluoro-2-methylpropyl]-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H](C)N2C[C@@H](CF)C)=CC=C(\C=C\C(O)=O)C=C1 CLDCRFJRMORRTI-IEGMAYJBSA-N 0.000 claims 1
- RZLKPYCEHAUODL-SDNWHVSQSA-N (e)-3-[4-[2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1=2NC3=CC=CC=C3C=2CC(C)(C)N(CC(C)(F)C)C1C1=CC=C(\C=C\C(O)=O)C=C1 RZLKPYCEHAUODL-SDNWHVSQSA-N 0.000 claims 1
- WRHLOSDZEZAYKX-WFSDQYTKSA-N (e)-3-[4-[2-[(2s)-3-fluoro-2-methylpropyl]-3,3-dimethyl-4,9-dihydro-1h-pyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid Chemical class C1=2NC3=CC=CC=C3C=2CC(C)(C)N(C[C@@H](CF)C)C1C1=CC=C(\C=C\C(O)=O)C=C1 WRHLOSDZEZAYKX-WFSDQYTKSA-N 0.000 claims 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (16)
1. Jedinjenje, naznačeno time, što ima Formulu (I) u kojoj: R1 i R2 su svaki nezavisno H ili F; R3 je H ili metil; i ili: a)R4 je H, a R5 je F; ili b)R4 je F, a R5 je H; ili neka njegova farmaceutski-prihvatljiva so.
2. Jedinjenje kao šta se zahteva u zahtevu 1, ili neka njegova farmaceutski-prihvatljiva so, naznačeno time, što ima formulu (IA).
3. Jedinjenje kao šta se zahteva u zahtevu 1 ili u zahtevu 2, ili neka njegova farmaceutski-prihvatljiva so, naznačeno time, što R3 je vodonik.
4. Jedinjenje kao šta se zahteva u bilo kojem od prethodnih zahteva, ili neka njegova farmaceutski-prihvatljiva so, naznačeno time, što R4 je vodonik, a R5 je fluoro.
5. Jedinjenje kao šta se zahteva u zahtevu 1 ili neka njegova farmaceutski-prihvatljiva so, naznačeno time, što je izabrano iz: (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(3,5-difluoro-4-((1R,3R)-2-((S)-3-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(4-((1R,3R)-2-((S)-3-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(3,5-difluoro-4-(2-((S)-3-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(3,5-difluoro-4-(2-(2-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(4-(2-((S)-3-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(4-(2-(2-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; (E)-3-(3-fluoro-4-(2-((S)-3-fluoro-2-metilpropil)-3,3-dimetil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline; i (E)-3-[4-[(1R,3R)-1-deuterio-2-(2-fluoro-2-metil-propil)-3-metil-4,9-dihidro-3H-pirido[3,4-b]indol-1-il]-3,5-difluoro-fenil]prop-2-enoične kiseline.
6. Jedinjenje kao šta se zahteva u zahtevu 5, naznačeno time, što je (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilna kiselina, pri čemu pomenuto jedinjenje ima sledeću strukturu: ili neka njegova farmaceutski-prihvatljiva so.
7. Jedinjenje kao šta se zahteva u zahtevu 6, naznačeno time, što je (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilna kiselina.
8. Jedinjenje kao šta se zahteva u zahtevu 6, naznačeno time, što je maleatna so (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilne kiseline.
9. Jedinjenje kao šta se zahteva u zahtevu 7 u kristalnoj formi, naznačeno time, što ima obrazac difrakcije X-zraka na prahu (XRPD) sa najmanje dva specifična šiljka kod 2-teta = 8.4° i 10.9° pri čemu pomenute vrednosti mogu da variraju plus ili minus 0.2° 2-teta.
10. Jedinjenje kao šta se zahteva u bilo kojem od prethodnih zahteva ili neka njegova farmaceutski-prihvatljiva so, naznačeno time, što se upotrebljava kao medikament.
11. Jedinjenje kao šta se zahteva u bilo kojem od zahteva od 1 do 9 ili neka njegova farmaceutski-prihvatljiva so, naznačeno time, što se upotrebljava u prevenciji ili tretmanu raka kod toplo-krvnih životinja poput čoveka.
12. Jedinjenje za upotrebu u prevenciji ili tretmanu raka, kao šta se zahteva u zahtevu 11, naznačeno time, što je (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilna kiselina, ili neka njena farmaceutski-prihvatljiva so.
13. Jedinjenje za upotrebu u tretmanu raka, ili neka njegova farmaceutski-prihvatljiva so, kao šta se zahteva u zahtevu 11 ili zahtevu 12, naznačeno time, što pomenuti rak je rak dojke ili ginekološki rak.
14. Farmaceutska kompozicija, naznačena time, što sadrži jedinjenje sa Formulom (I) ili neku njegovu farmaceutski-prihvatljivu so, kao šta se zahteva u bilo kojem od zahteva od 1 do 9, i neki farmaceutski-prihvatljivi razređivač ili nosilac.
15. Farmaceutska kompozicija u skladu sa zahtevom 14 koja sadrži (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-metilpropil)-3-metil-2,3,4,9-tetrahidro-1H-pirido[3,4-b]indol-1-il)fenil)akrilnu kiselinu ili neku njezinu farmaceutski-prihvatljivu so, zajedno sa barem jednim farmaceutski-prihvatljivim razređivačem ili nosiocem, naznačena time, što pomenuta kompozicija sadrži manje od 5% w/w (R,E)-3-(3,5-difluoro-4-(2-(2-fluoro-2-metilpropil)-3-metil-4,9-dihidro-3H-pirido[3,4-b]indol-2-ium-1-il)fenil)akrilata.
16. Farmaceutska kompozicija u skladu sa zahtevom 15, naznačena time, što pomenuta kompozicija dodatno sadrži neki anti-oksidans i opciono dodatno sadrži neki metalo-helatni agens.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827951P | 2013-05-28 | 2013-05-28 | |
| US201361915685P | 2013-12-13 | 2013-12-13 | |
| PCT/GB2014/051607 WO2014191726A1 (en) | 2013-05-28 | 2014-05-27 | Chemical compounds |
| EP14727036.7A EP3004090B1 (en) | 2013-05-28 | 2014-05-27 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02892B true ME02892B (me) | 2018-04-20 |
Family
ID=50841880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-292A ME02892B (me) | 2013-05-28 | 2014-05-27 | Hemijska jedinjenja |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US9155727B2 (me) |
| EP (2) | EP3360875A1 (me) |
| JP (1) | JP6286031B2 (me) |
| KR (1) | KR20160013198A (me) |
| CN (1) | CN105229004B (me) |
| AP (1) | AP2015008858A0 (me) |
| AU (1) | AU2014272856B2 (me) |
| BR (1) | BR112015029455A8 (me) |
| CA (1) | CA2911859A1 (me) |
| CL (1) | CL2015003491A1 (me) |
| CR (1) | CR20150629A (me) |
| CY (1) | CY1120474T1 (me) |
| DK (1) | DK3004090T3 (me) |
| DO (1) | DOP2015000274A (me) |
| ES (1) | ES2654161T3 (me) |
| HR (1) | HRP20171961T1 (me) |
| HU (1) | HUE035738T2 (me) |
| IL (1) | IL242559B (me) |
| LT (1) | LT3004090T (me) |
| ME (1) | ME02892B (me) |
| MX (1) | MX361538B (me) |
| NI (1) | NI201500167A (me) |
| PE (1) | PE20160874A1 (me) |
| PH (1) | PH12015502615B1 (me) |
| PL (1) | PL3004090T3 (me) |
| PT (1) | PT3004090T (me) |
| RS (1) | RS56678B1 (me) |
| RU (1) | RU2664109C2 (me) |
| SG (1) | SG11201509393VA (me) |
| SI (1) | SI3004090T1 (me) |
| SM (1) | SMT201700589T1 (me) |
| TN (1) | TN2015000516A1 (me) |
| TW (1) | TWI653235B (me) |
| UY (1) | UY35590A (me) |
| WO (1) | WO2014191726A1 (me) |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| DK2997019T3 (en) | 2013-05-17 | 2018-12-03 | Janssen Sciences Ireland Uc | SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| HRP20180791T1 (hr) | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| CA2936947A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| JP2018510159A (ja) | 2015-03-19 | 2018-04-12 | ノヴィラ・セラピューティクス・インコーポレイテッド | アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法 |
| US10087191B2 (en) | 2015-06-16 | 2018-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2017024318A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| TW201718496A (zh) | 2015-09-29 | 2017-06-01 | 諾維拉治療公司 | B型肝炎抗病毒劑之晶型 |
| KR20240142622A (ko) * | 2015-10-01 | 2024-09-30 | 올레마 파마슈티컬스 인코포레이티드 | 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물 |
| JP6592197B2 (ja) * | 2015-11-12 | 2019-10-16 | 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． | アクリル酸誘導体、製造方法、および医薬としてのその使用 |
| LT3386500T (lt) | 2015-12-09 | 2022-12-27 | The Board Of Trustees Of The University Of Illinois | Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu |
| CA3006683A1 (en) | 2015-12-22 | 2017-06-29 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
| KR102479822B1 (ko) | 2016-02-05 | 2022-12-21 | 인벤티스바이오 엘엘씨 | 선택적 에스트로겐 수용체 분해제 및 이들의 용도 |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| JP7131773B2 (ja) * | 2016-04-29 | 2022-09-06 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | ホルモン受容体に関連する転写活性の標的尺度 |
| WO2017197904A2 (zh) * | 2016-05-08 | 2017-11-23 | 上海诚妙医药科技有限公司 | 帕布昔利布的新晶型及其制备方法及其用途 |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| CN109843882A (zh) | 2016-06-16 | 2019-06-04 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| EP3472162B1 (en) * | 2016-06-16 | 2021-11-17 | F. Hoffmann-La Roche AG | Heteroaryl estrogen receptor modulators and uses thereof |
| WO2018001232A1 (zh) * | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| US10149839B2 (en) | 2016-07-25 | 2018-12-11 | Astrazeneca Ab | Chemical compounds |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| JP7050770B2 (ja) * | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| EP3640251B1 (en) | 2016-10-24 | 2021-12-08 | Astrazeneca AB | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| WO2018130123A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的五环类化合物及其应用 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| PL3494116T3 (pl) * | 2017-01-30 | 2020-04-30 | Astrazeneca Ab | Modulatory receptora estrogenowego |
| JP7227912B2 (ja) | 2017-02-08 | 2023-02-24 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キメラ抗原受容体の調節 |
| KR20190117582A (ko) | 2017-02-10 | 2019-10-16 | 쥐원 쎄라퓨틱스, 인크. | 벤조티오펜 에스트로겐 수용체 조정제 |
| CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
| CN110536888B (zh) * | 2017-06-20 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| WO2019006393A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of git38 and methods of manufacture thereof |
| AU2018351050B2 (en) | 2017-10-18 | 2025-09-18 | Novartis Ag | Compositions and methods for selective protein degradation |
| EA038160B1 (ru) * | 2017-11-30 | 2021-07-15 | Астразенека Аб | Модуляторы рецептора эстрогена |
| CN109867659A (zh) * | 2017-12-04 | 2019-06-11 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物的制备方法 |
| US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| WO2019162429A1 (en) * | 2018-02-23 | 2019-08-29 | Center For Intelligent Research In Crystal Engineering, S.L. | Cocrystals of ubiquinol and compositions comprising them |
| MX2020009531A (es) | 2018-03-14 | 2020-10-05 | Janssen Sciences Ireland Unlimited Co | Regimen posologico del modulador del ensamblaje de la capside. |
| CA3099155A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2019228443A1 (en) * | 2018-05-30 | 2019-12-05 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Selective estrogen receptor downregulators and uses thereof |
| CR20200621A (es) | 2018-06-21 | 2021-02-03 | Hoffmann La Roche | Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso |
| JP2021529757A (ja) | 2018-07-03 | 2021-11-04 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 小胞体ストレス応答の活性剤 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| MX2021007687A (es) | 2018-12-24 | 2021-10-13 | Inventisbio Co Ltd | Sales novedosas de degradadores selectivos de receptores de estrogeno. |
| WO2020169784A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20220034129A (ko) | 2019-07-07 | 2022-03-17 | 올레마 파마슈티컬스 인코포레이티드 | 에스트로겐 수용체 길항제 요법 |
| KR20220044528A (ko) | 2019-08-06 | 2022-04-08 | 리커리엄 아이피 홀딩스, 엘엘씨 | 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제 |
| AU2020380211A1 (en) * | 2019-11-04 | 2022-05-19 | Recurium Ip Holdings, Llc | Salts and forms of an estrogen receptor modulator |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| KR20220119415A (ko) | 2019-12-20 | 2022-08-29 | 씨4 테라퓨틱스, 인코포레이티드 | Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물 |
| CN114746424B (zh) | 2020-01-10 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
| TW202146412A (zh) | 2020-03-05 | 2021-12-16 | 美商Ｃ４醫藥公司 | 用於標靶降解brd9之化合物 |
| CA3169679A1 (en) | 2020-03-06 | 2021-09-10 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| MX2022013258A (es) | 2020-04-24 | 2022-11-14 | Astrazeneca Ab | Formulaciones farmaceuticas. |
| MX2022013391A (es) | 2020-04-24 | 2022-11-30 | Astrazeneca Ab | Pauta posologica para el tratamiento del cancer. |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| IL300397A (en) | 2020-08-05 | 2023-04-01 | C4 Therapeutics Inc | Compounds for targeted knockdown of RET |
| MX2023001572A (es) * | 2020-08-05 | 2023-05-08 | Aizant Drug Res Solutions Private Limited | Formas farmaceuticas sólidas de palbociclib. |
| EP4247977A2 (en) | 2020-11-23 | 2023-09-27 | Sanofi | Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer |
| EP4267578A4 (en) | 2020-12-23 | 2024-11-20 | Recurium IP Holdings, LLC | ESTROGEN RECEPTOR MODULATORS |
| MX2023011241A (es) | 2021-03-23 | 2023-10-03 | Nuvation Bio Inc | Compuestos dirigidos a receptores de hormonas nucleares contra el cancer. |
| JP2024516024A (ja) | 2021-05-03 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | 抗がん核内ホルモン受容体標的化化合物 |
| MX2023014059A (es) | 2021-06-08 | 2024-03-12 | C4 Therapeutics Inc | Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante. |
| WO2023283329A1 (en) * | 2021-07-08 | 2023-01-12 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| AU2022307207A1 (en) | 2021-07-09 | 2024-02-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Salt types of tricyclic tetrahydro isoquinoline derivative |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
| WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
| EP4611901A1 (en) | 2022-11-04 | 2025-09-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| KR20240170460A (ko) * | 2023-05-25 | 2024-12-03 | 주식회사 삼양홀딩스 | 팔보시클립의 경구용 조성물 |
| EP4735452A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras protein |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| AU2381497A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| YU72201A (sh) | 1999-04-28 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | Derivati di-aril kiseline kao ppar receptorski ligandi |
| FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| HK1054039B (zh) * | 2000-03-15 | 2010-04-16 | 萨诺费－阿文蒂斯德国有限公司 | 取代的β-咔啉 |
| US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
| JP2005516967A (ja) | 2002-01-18 | 2005-06-09 | ザ ジェネティクス カンパニー インコーポレーティッド | β−セクレターゼインヒビター |
| EP1496905B1 (en) | 2002-04-22 | 2008-08-13 | Johns Hopkins University School of Medicine | Modulators of hedgehog signaling pathways, compositions and uses related thereto |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| US7872133B2 (en) | 2003-06-23 | 2011-01-18 | Ono Pharmaceutical Co., Ltd. | Tricyclic heterocycle compound |
| EP1667955A2 (en) * | 2003-07-28 | 2006-06-14 | SmithKline Beecham Corporation | Cycloalkylidene compounds as modulators of the estrogen receptor |
| DE10335725A1 (de) | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate |
| CN1910183A (zh) * | 2004-01-23 | 2007-02-07 | 希龙公司 | 四氢咔啉化合物作为抗癌药 |
| US7714132B2 (en) * | 2004-03-11 | 2010-05-11 | Actelion Pharmaceuticals, Ltd. | Tetrahydropyridoindole derivatives |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| AU2005302409A1 (en) | 2004-10-28 | 2006-05-11 | The Institutes For Pharmaceutical Discovery Llc | Substituted carboxylic acids |
| EP1836182A2 (en) | 2004-11-18 | 2007-09-26 | The Institutes for Pharmaceutical Discovery, LLC | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
| US7772245B2 (en) | 2005-02-14 | 2010-08-10 | Miikana Therapeutics, Inc. | Inhibitors of histone deacetylase |
| WO2006101434A1 (en) * | 2005-03-22 | 2006-09-28 | Astrazeneca Ab | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS |
| US20070032385A1 (en) | 2005-06-20 | 2007-02-08 | Dunetz Joshua R | Sustainable chemical processes |
| US20080075692A1 (en) | 2006-05-09 | 2008-03-27 | Perrine Susan P | Methods for treating blood disorders |
| CA2659851C (en) | 2006-08-23 | 2014-02-25 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| EP2130908A3 (en) | 2006-08-29 | 2010-01-06 | Reinnervate Limited | Retinoid compounds and their use |
| WO2008124838A1 (en) | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Compounds that inhibit human dna ligases and methods of treating cancer |
| WO2008124836A2 (en) | 2007-04-10 | 2008-10-16 | Uwm Research Foundation, Inc. | Methods of reducing virulence in bacteria |
| US20100158858A1 (en) | 2007-04-13 | 2010-06-24 | Liangxian Cao | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
| CA2728301A1 (en) * | 2008-07-03 | 2010-01-07 | Osteogenex Inc. | Vinpocetine and eburnamonine derivatives for promoting bone growth |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| US20120202801A1 (en) | 2009-05-27 | 2012-08-09 | Liangxian Cao | Methods for treating breast cancer |
| MX373926B (es) * | 2009-05-27 | 2020-07-10 | Ptc Therapeutics Inc | Metodos para tratar cancer y estados no neoplasicos. |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
-
2014
- 2014-05-27 UY UY0001035590A patent/UY35590A/es not_active Application Discontinuation
- 2014-05-27 BR BR112015029455A patent/BR112015029455A8/pt not_active Application Discontinuation
- 2014-05-27 KR KR1020157036820A patent/KR20160013198A/ko not_active Ceased
- 2014-05-27 RU RU2015151502A patent/RU2664109C2/ru active
- 2014-05-27 DK DK14727036.7T patent/DK3004090T3/en active
- 2014-05-27 CN CN201480028785.1A patent/CN105229004B/zh not_active Expired - Fee Related
- 2014-05-27 ES ES14727036.7T patent/ES2654161T3/es active Active
- 2014-05-27 AP AP2015008858A patent/AP2015008858A0/xx unknown
- 2014-05-27 PL PL14727036T patent/PL3004090T3/pl unknown
- 2014-05-27 SI SI201430531T patent/SI3004090T1/en unknown
- 2014-05-27 TW TW103118498A patent/TWI653235B/zh not_active IP Right Cessation
- 2014-05-27 SM SM20170589T patent/SMT201700589T1/it unknown
- 2014-05-27 EP EP17196495.0A patent/EP3360875A1/en not_active Withdrawn
- 2014-05-27 PT PT147270367T patent/PT3004090T/pt unknown
- 2014-05-27 AU AU2014272856A patent/AU2014272856B2/en not_active Ceased
- 2014-05-27 SG SG11201509393VA patent/SG11201509393VA/en unknown
- 2014-05-27 HR HRP20171961TT patent/HRP20171961T1/hr unknown
- 2014-05-27 CA CA2911859A patent/CA2911859A1/en not_active Abandoned
- 2014-05-27 TN TN2015000516A patent/TN2015000516A1/en unknown
- 2014-05-27 PE PE2015002429A patent/PE20160874A1/es active IP Right Grant
- 2014-05-27 RS RS20171304A patent/RS56678B1/sr unknown
- 2014-05-27 WO PCT/GB2014/051607 patent/WO2014191726A1/en not_active Ceased
- 2014-05-27 MX MX2015016428A patent/MX361538B/es active IP Right Grant
- 2014-05-27 JP JP2016516235A patent/JP6286031B2/ja not_active Expired - Fee Related
- 2014-05-27 HU HUE14727036A patent/HUE035738T2/en unknown
- 2014-05-27 US US14/287,332 patent/US9155727B2/en not_active Expired - Fee Related
- 2014-05-27 ME MEP-2017-292A patent/ME02892B/me unknown
- 2014-05-27 LT LTEP14727036.7T patent/LT3004090T/lt unknown
- 2014-05-27 EP EP14727036.7A patent/EP3004090B1/en active Active
-
2015
- 2015-08-31 US US14/840,342 patent/US9616050B2/en not_active Expired - Fee Related
- 2015-11-11 DO DO2015000274A patent/DOP2015000274A/es unknown
- 2015-11-12 IL IL242559A patent/IL242559B/en not_active IP Right Cessation
- 2015-11-24 PH PH12015502615A patent/PH12015502615B1/en unknown
- 2015-11-27 CL CL2015003491A patent/CL2015003491A1/es unknown
- 2015-11-27 NI NI201500167A patent/NI201500167A/es unknown
- 2015-11-30 CR CR20150629A patent/CR20150629A/es unknown
-
2017
- 2017-02-28 US US15/445,000 patent/US10130617B2/en not_active Expired - Fee Related
-
2018
- 2018-01-03 CY CY20181100009T patent/CY1120474T1/el unknown
- 2018-10-12 US US16/158,527 patent/US20190038607A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02892B (me) | Hemijska jedinjenja | |
| JP2016522835A5 (me) | ||
| MY173946A (en) | (6s,9as)-n-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl) azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1h-pyrazino[2,1-c] [1,2,4]triazine-1-carboxamide compound | |
| CA2826751C (en) | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds | |
| ME02729B (me) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| ME02452B (me) | Sredstva za induciranje apoptoze namijenjena liječenju raka i imunih i autoimunih bolesti | |
| JP2015078230A5 (me) | ||
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| JP2013032389A5 (me) | ||
| NZ714558A (en) | Formulation comprising a hypolipidemic agent | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| MY160785A (en) | Manufacturing process for pyrimidine derivatives | |
| NZ716840A (en) | Combination formulation of two antiviral compounds | |
| JP2017514910A5 (me) | ||
| JO3221B1 (ar) | مركبات حمض داي ميثيل - بنزويك مفيدة لعلاج الحالات الالتهابية | |
| JP2015500842A5 (me) | ||
| NZ712660A (en) | Dicarboxylic acid compound | |
| PH12015501945B1 (en) | Formulations of organic compounds | |
| WO2014014794A3 (en) | Mineralocorticoid receptor antagonists | |
| SI3083605T1 (en) | COMPOUNDS OF FLUOROFENYL PIRAZOLE | |
| HRP20161691T1 (hr) | Derivati ariletinila | |
| JP2016501844A5 (me) | ||
| JP2014508170A5 (me) | ||
| JP2014144922A5 (me) |